FDA Requires Added Warning on Labeling of Novartis’ MS Drug

Drug Industry Daily
A A
The FDA said it instructed Novartis to place a new warning on labeling for its multiple sclerosis treatment Gilenya (fingolimod) and the agency issued a warning that abruptly ending treatment can severely exacerbate the disease.

To View This Article:

Login

Subscribe To Drug Industry Daily